SARS-CoV-2 Infection in Iranian People Living with Human Immunodeficiency Virus-1 Infection

Saba Garshasbi ¹, Farah Bokharaei-Salim ^{2,*}, Khadijeh Khanaliha ³, Seyed Jalal Kiani ², Saeed Kalantari ⁴, Mahin Jamshidi Makiani ⁵, Arezoo Marjani ⁶, Farzaneh Dehghani-Dehej ⁷, Roghayeh Babaei ⁷, Mohsen Sadeghi ⁷ and Mohammad Abbassi-Kolli ⁷

¹Department of Molecular Medicine, Faculty of Advanced Technologies in Medicine, Iran University of Medical Sciences, Tehran, Iran

²School of Medicine, Iran University of Medical Sciences, Tehran, Iran

³Research Center of Pediatric Infectious Diseases, Institute of Immunology and Infectious Diseases, Iran University of Medical Sciences, Tehran, Iran

⁴Department of Infectious Diseases and Tropical Medicine, Iran University of Medical Sciences, Tehran, Iran

⁵Antimicrobial Resistance Research Center, Institute of Immunology and Infectious Diseases, Iran University of Medical Sciences, Tehran, Iran

⁶Department of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran

⁷Deputy of Health, Iran University of Medical Sciences, Tehran, Iran

*Corresponding author: School of Medicine, Iran University of Medical Sciences, Tehran, Iran. Email: bokharaeifarrah@gmail.com

Received 2021 December 17; Revised 2022 February 09; Accepted 2022 February 11.

Abstract

Background: A novel Coronavirus first emerging in Wuhan, China, was named severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2). The disease caused by SARS-CoV-2 is known as Coronavirus disease 2019 (COVID-19). HIV-1 infected individuals may be at risk of COVID-19.

Objectives: This cross-sectional study evaluated the SARS-CoV-2 infection rate and COVID-19 prevalence among Iranian HIV-1-infected people.

Methods: The study was conducted on 155 HIV-1-infected patients from June 2020 to October 2020. COVID-19 Ab (IgG) was detected using an enzyme immunoassay in serum specimens. Furthermore, nasopharyngeal and oropharyngeal specimens were collected. Then, the genomic RNA of SARS-CoV-2 was detected using a real-time polymerase chain reaction (RT-PCR). Clinical symptoms of the studied participants with and without COVID-19 were examined.

Results: Of 155 HIV-1-infected individuals, 12 (7.7%) had positive real-time PCR results for SARS-CoV-2. Out of 12 (7.7%) patients with COVID-19, four (33.3%) were males. Anti-COVID Ab (IgG) was detected in 10 (6.5%) participants, of whom eight (80.0%) were males. The most common COVID-19 clinical symptoms, including dry cough, fever, runny nose, anosmia, and hypogeusia, were observed in seven (58.3%), five (41.7%), five (41.7%), five (41.7%), and five (41.7%) patients with COVID-19, respectively.

Conclusions: A recent study has shown that the risk of SARS-CoV-2 infection in HIV-infected individuals is similar to that in the general population.

Keywords: HIV-1 Infection, SARS-CoV-2, COVID-19, Clinical Symptoms

1. Background

To date, human Coronaviruses have led to three epidemics, including severe acute respiratory syndrome Coronavirus (SARS-CoV), middle east respiratory syndrome Coronavirus (MERS-CoV), and severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2). The emerging Coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 was first reported in Wuhan, China, in 2019. This pandemic has marked one of the century's catastrophes (1). Coronavirus disease 2019 is clinically diverse and widespread so that most people with COVID-19 often have mild and no severe symptoms of the disease while a few experience severe

COVID-19, requiring care, oxygen support, and hospitalization. Moreover, many patients are admitted to intensive care units (2). Manifestations may be asymptomatic. Mild symptoms such as fever and cough or more severe symptoms such as acute respiratory distress syndrome (ARDS) may also occur, eventually leading to death (3). Following SARS-CoV-2, lymphopenia occurs, resulting in a cytokine storm. It also causes pathological problems in the lungs, liver, heart, and other body organs (4).

Worldwide, approximately 24 million people have been identified with SARS-CoV-2. Older people with risk factors and chronic diseases, including obesity, respiratory disease, diabetes, cardiovascular disease (CVD), and high

blood pressure (hypertension), have more severe symptoms and higher mortality and morbidity rates. Further, many HIV-infected people are at risk of COVID-19 (5). Little is known about the HIV impact on COVID-19. Individuals infected with HIV-1 are usually immunocompromised, and it is unclear how a suppressed immune system leads to SARS-CoV-2 (6). According to the World Health Organization (WHO) latest statistics, it was estimated that by the end of 2019, about 38.0 million people would be infected with HIV (7). Besides, HIV-1-infected people, particularly those with low CD4 cell counts, possibly are at an increased risk for severe diseases or COVID-19, and the HIV viral load is not suppressed in these people (8). The regular consumption of antiretrovirals (ARVs), including nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), and protease inhibitors (PIs) and immunosuppressors, might change clinical manifestations and risk of COVID-19 in HIV-1-infected individuals (9).

Previous studies of MERS-CoV and SARS-CoV have mostly reported a lower risk of severe disease in HIV-infected patients. These studies report the inhibition of Coronavirus replication by ARVs to reduce Coronavirus risk in HIV-infected individuals. However, due to the suppression of the immune system, the disease lasts longer in these patients (10). Probably, the risk of COVID-19 increases in HIV-infected individuals with a high HIV viral load and low CD4 cell count (8). On the other hand, protection against cytokine storms due to SARS-CoV-2 has been reported by reducing the number of CD4 cell counts and suppressing the immune system in HIV-1-infected individuals (11). However, subsequent research has reported that COVID-19 severity is associated with low CD4 cell counts (12).

Several researchers believe that high sensitivity to SARS-CoV-2 results from the suppression of the immune system by HIV, while others believe that these people have less risk and complications due to problems associated with cellular immunity. Besides, HIV-1-infected individuals probably have lower inflammation, reducing COVID-19-induced cytokine storm (13). Moreover, researchers have different opinions about the effectiveness of ARVs against COVID-19 (14). Although there is no exact information about the risk of infection with SARS-CoV-2 in HIV-1-infected individuals, these individuals are probably at greater risk of COVID-19 (15). After the COVID-19 pandemic, about 19% of HIV-1-infected individuals reportedly did not have access to ARVs (16). In HIV-infected patients, the use of ARVs has increased life expectancy, but the COVID-19 pandemic, along with HIV, has posed significant challenges in managing and controlling this group of patients (17). So far, not much research has reported the epidemiological

features and clinical outcomes of patients with HIV/SARS-CoV-2 confection. Following the COVID-19 pandemic, concerns have been raised about the lack of data, particularly in countries with high HIV rates, including Sub-Saharan Africa, which accounts for 70% of HIV infections (18).

2. Objectives

This study evaluated the SARS-CoV-2 infection rate and COVID-19 prevalence among Iranian HIV-1-infected patients.

3. Methods

3.1. Patients Selection

From June 2020 to October 2020, 155 consecutive Iranian HIV-1-infected patients were examined in this cross-sectional study. These patients were treated in clinics or hospitals affiliated with the Iran University of Medical Sciences (IUMS), Tehran, Iran. The treatment regimen of these 155 individuals was as follows: (1) NRTIs and NNRTIs-based regimens in 110 (70.5%); (2) NRTIs and PIs-based regimens in 10 (6.4%); (3) NRTIs, PIs, and INIs-based regimens in two (1.3%); (4) NRTIs, NNRTIs, and PIs-based regimens in four (2.6%); and (5) NRTIs, NNRTIs, PIs, and INIs-based regimens in two (1.3%). One (1.3%) patient was not taking any antiretroviral drugs.

3.2. Sample Collection

Nasopharyngeal and oropharyngeal samples were taken from HIV-1-infected patients, placed in the virus transport medium (VTM), and sent to the laboratory to diagnose infection with the COVID-19 virus. To detect antibodies against the virus, 3 mL of the peripheral blood was taken from the participants, and the plasma of the samples was separated by centrifugation and then frozen at -80°C until use.

3.3. Detection of COVID-19 Ab (IgG) in Serum Using Enzyme Immunoassay (EIA)

COVID-19 Ab (IgG) in serum samples was analyzed using an enzyme immunoassay (EIA) kit (Euroimmun Medizinische Labordiagnostika, Lubeck, Germany) according to the manufacturer's instructions.

3.4. Viral RNA Extraction and cDNA Synthesis

Viral RNA was isolated from the nasopharyngeal and oropharyngeal samples using a High Pure Viral Nucleic Acid (Roche Diagnostics GmbH, Mannheim, Germany) kit, according to the manufacturer's instructions. The quality and quantity of the extracted viral RNA were determined by a nanodrop spectrophotometer (Thermo Scientific, Wilmington, MA) and kept at -20°C. The cDNA synthesis was carried out at 42°C for 30 min in a 20 µL reaction mixture containing random hexamer (20 pmol), 5 X reverse transcriptase (RT) reaction buffer (4 µL), 102 U of Moloney murine leukemia virus (MMuLV) reverse transcriptase (Fermentas GmbH, St. LeonRot, Germany), 18.4 U of RNase inhibitor (Fermentas GmbH, St. Leon-Rot, Germany), dNTPs (100 mmol), 1.0 µL of DEPC-treated water, and 0.5 mg of the isolated RNA. The reverse transcriptase enzyme was inactivated after cDNA synthesis at 72°C for 10 min.

3.5. SARS-CoV-2 Detection by Real-Time Polymerase Chain Reaction

The envelope (E) and RdRp (RNA-dependent RNA polymerase) regions of SARS-CoV-2 in the extracted RNA were detected using real-time polymerase chain reaction (RT-PCR) with specific primers and TaqMan probes for these regions (E, RdRp genes) (19), using RNase P as an internal control (20) (Table 1). The Rotor-Gene Q (QIAGEN, Germany) instrument was used for the experiment. For positive and negative controls, the nasopharyngeal and oropharyngeal specimens of five patients with SARS-CoV-2 infection and five healthy people were used, respectively. Briefly, the real-time PCR was carried out using 25 µL reaction mixtures containing 12.5 µL Premix Ex TaqTM (probe qPCR) (TaKaRa Bio Inc. Shiga, Japan), 10 pmol each specific primer and 5 pmol each TaqMan probe for E, RdRp genes, with RNase P and 5 µL of the cDNA as a template. The reaction was carried out at 95°C for 10 min and 40 cycles of amplification (95°C for 10 s and 60°C for 40 s).

3.6. Statistical Analysis

Statistical analysis was conducted by SPSS version 20 software (SPSS Inc., Chicago, IL, USA). The Kolmogorov-Smirnov test was used to assess the normality of the data. The chi-square test or Fisher's exact test determined the statistical differences between categorical variables. A P value of less than 0.05 was considered statistically significant.

4. Results

All 155 HIV-1-infected patients (anti-HIV Abs and HIV-RNA positive) referred to the clinics and hospitals affiliated

with IUMS, Tehran, Iran, were enrolled in the present research. The mean age of the patients was 43.2 ± 11.3 years (range 16 - 68 years). Of the 155 participants, 109 (70.3%) were males. Demographic and epidemiological characteristics and laboratory data are presented in Table 2. The genomic RNA of SARS-CoV-2 was detected in the nasopharyngeal and oropharyngeal samples of 12 (7.7%) HIV-infected individuals, of whom four (33.3%) were males. It is noteworthy that 10 (6.5%) subjects were positive for antibodies against the virus, so they had already been infected with SARS-CoV-2 and had antibodies against it (Table 2).

The mean viral load of the studied patients was 320.9 ± 1542 IU/mL (range 0 - 11136). The mean CD4 count of the patients was 604.8 ± 303 cells/µL (range 65 - 1481). The mean duration of HIV infection was 6.1 ± 5.2 years (range 1 - 19). Injecting drug use (IDU), history of unprotected sex, history of needle sticks, and history of imprisonment were positive in 60 (38.7%), 85 (54.8%), 40 (25.8%), and 50 (32.3%) patients, respectively. Also, concerning the routes of HIV infection, IDU, sexual relationship, mother to child transmission, and unknown routes were reported in 48 (31.0%), 83 (53.5%), two (1.3%), and 22 (14.2%) patients, respectively. Anti-COVID Ab (IgG) was detected in 10 (6.5%). However, the real-time PCR result for SARS-CoV-2 infection was positive in 12 (7.7%) (Table 2).

Clinical symptoms of the studied HIV-1-infected participants with positive and negative results of real-time PCR for SARS-CoV-2 infection were evaluated for various symptoms such as fever, confusion, headache, chills, and runny nose, among others. In HIV-1-infected patients with SARS-CoV-2, the most common clinical symptoms were dry cough in seven (58.3%), fever in five (41.7%), runny nose in five (41.7%), smell dysfunction in five (41.7%), and taste dysfunction in five (41.7%). Furthermore, HCV Ab was detected in four (33.3%) of the HIV-infected individuals diagnosed with COVID-19. In addition, 10 (83.3%) of these patients showed HBsAb. However, none of the HIV-1-infected individuals with SARS-CoV-2 infection were detected with HBsAg, diabetes, tuberculosis (TB), and Kaposi's sarcoma (Table 3).

In this study, the participants had different types of blood groups. Out of 12 (7.7%) positive real-time PCR results for SARS-CoV-2, the numbers of HIV-1-infected patients with the O+ blood group, A+ blood group, B+ blood group, and AB+ blood group were four, three, three, and two, respectively. Out of 10 (6.5%) positive results for anti-COVID Ab (IgG), the numbers of HIV-1-infected patients with the O+ blood group, O- blood group, and A+ blood group were six, two, and two, respectively (Table 4).

Table 1. Primers and Probes for Detection of E and RdRp Regions of COVID-19 Virus Using Real-Time Polymerase Chain Reaction (1)

Assay Use and Polarity	Names	Sequences
E		
Forward primer	E-Sarbeco	ACA GGT ACG TTA ATA GTT AAT AGC GT
Reverse primer	E-Sarbeco	ATA TTG CAG CAG TAC GCA CAC A
Probe	E-Sarbeco	FAM- ACA CTA GCC ATC CTT ACT GCG CTT CG -BBQ
RdRp		
Forward primer	RdRP-SARSR	GTG ARA TGG TCA TGT GTG GCG G
Reverse primer	RdRP-SARSR	CAR ATG TTA AAS ACA CTA TTA GCA TA
Probe	RdRP-SARSR	VIC- CAG GTG GAA CCT CAT CAG GAG ATG C -BBQ
RNase p		
Forward primer	RP2-F	AGA TTT GGA CCT GCG AGC G
Reverse primer	RP2-R	GAG CGG CTG TCT CCA CAA GT
Probe	RP2-probe	ROX- TTC TGA CCT GAA GGC TCT GCG CG -BBQ

Abbreviations: E, envelope; RdRp, RNA-dependent RNA polymerase; RNase P, ribonuclease P.

5. Discussion

It is currently known that most individuals, including pregnant women and children, are at risk of infection with SARS-CoV-2. Several studies have shown that older individuals are more susceptible to COVID-19 and usually have symptoms such as cough, fever, headache, and fatigue (21, 22). To our knowledge, this study is the first study on COVID-19 diagnosis in Iranian people with HIV infection. In this study, the COVID-19 infection rate in HIV-infected individuals was observed to be 7.7% (n = 12). The COVID-19 diagnosis rate was higher in females (n = 8, 17.4%) than males (n = 4, 3.7%). The participants were evaluated for various symptoms such as fever, confusion, headache, chills, and runny nose. In patients with SARS-CoV-2, the most common symptoms were dry cough (n = 7, 58.3%), fever (n = 5, 41.7%), runny nose (n = 5, 41.7%), anosmia (n = 5, 41.7%), and hypogeusia (n = 5, 41.7%). Our data demonstrated that HCV Ab was detected in four (33.3%), and HBsAb was detected in 10 (83.3%) HIV-infected patients with COVID-19. In the present study, none of the patients with the positive result of real-time PCR for SARS-CoV-2 was detected with HBsAg, diabetes, tuberculosis (TB), and Kaposi's sarcoma.

According to previous studies, a low rate of CD4 cell counts and suppressed immune systems may have a protective effect on HIV-infected patients against the cytokine storm created in individuals with COVID-19 (11). However, factors related to COVID-19 severity, including high levels of interleukin-6 and low rate of platelet counts or lymphocytes, are associated with a low rate of CD4 cell counts (23). Since low CD4 counts do not relate to COVID-19, the disease severity is likely to be affected by immunosuppression

and appears to be associated with SARS-CoV-2 persistence and detrimental outcomes (12). Findings have demonstrated that COVID-19 in HIV-infected individuals due to immunosuppression can delay the SARS-CoV-2 clearance. However, the clinical recovery of COVID-19 was better in HIV-infected patients than in non-HIV-infected individuals (18, 24). Moreover, some studies demonstrated that the HIV viral load affected antibody levels against SARS-CoV-2. Infection with HIV is likely to influence the immune system's response to SARS-CoV-2, leading to harmful outcomes and permanence of SARS-CoV-2. It has recently been shown that the risk of severe COVID-19 manifestations is higher in people infected with HIV for a long time (25). Research has indicated that approximately 14% of individuals infected with SARS-CoV-2 have experienced severe illness, and about 6% have serious conditions (26).

Several studies have reported that decreased immune system potency is associated with aging (27). In previous studies, old age was a leading cause of death in MERS and SARS (28, 29). Moreover, studies have shown that women are less likely to be infected with SARS-CoV and MERS-CoV than men (30, 31). No agreement has been reached on using ARVs to prevent or treat COVID-19 (32). In HIV-1-infected individuals, the outcome and clinical stages of COVID-19 are not yet known. Several researchers have reported that HIV-1-infected individuals on ARV treatment may experience a lower risk of COVID-19 and relevant complications. As a result, the risk of severe lung failure is reduced (33). Conversely, other researchers have reported an incremental risk of COVID-19 due to the suppression of the immune system due to HIV-1 infection (13). The use of ARVs during the COVID-19 pandemic is essential for maintaining health

Table 2. Demographic Features, Laboratory, and Epidemiological Parameters of Studied Participants ^a

Parameters	Male	Female	Total
HIV-1-infected participants			
No. of patients	109 (70.3)	46 (29.7)	155 (100)
Age (y)	43.2 ± 11.3 (16 - 68)	43.0 ± 11.5 (26 - 68)	43.2 ± 11.3 (16 - 68)
Laboratory data			
Viral Load (IU/mL)	443.6 ± 1827 (0 - 11136)	30.2 ± 68 (0 - 214)	320.9 ± 1542 (0 - 11136)
CD4 count	573.4 ± 298 (65 - 1268)	679.2 ± 305 (67 - 1481)	604.8 ± 303 (65 - 1481)
Anti-COVID Ab (IgG)	8 (7.3)	2 (4.3)	10 (6.5)
PCR result for COVID-19	4 (3.7)	8 (17.4)	12 (7.7)
Epidemiological characteristics			
Duration of HIV infection (y)	6.3 ± 5.1 (1 - 19)	5.7 ± 5.3 (1 - 19)	6.1 ± 5.2 (1 - 19)
Intravenous drug users	46 (42.2)	14 (30.4)	60 (38.7)
History of unprotected sex	67 (61.5)	18 (39.1)	85 (54.8)
History of needle stick	40 (36.7)	0 (0.0)	40 (25.8)
History of imprisonment	50 (45.9)	0 (0.0)	50 (32.3)
Route of HIV infection			
Intravenous drug use	48 (44.0)	0 (0.0)	48 (31.0)
Sexual relationship	45 (41.3)	38 (82.8)	83 (53.5)
Mother to child	2 (12.8)	0 (0.0)	2 (1.3)
Unknown	14 (12.8)	8 (17.4)	22 (14.2)
Marital status			
Single	43 (39.4)	5 (10.9)	48 (31.0)
Married	45 (11.1)	24 (52.2)	69 (44.5)
Divorced	14 (12.8)	11 (23.9)	25 (16.1)
Widow	7 (6.4)	6 (13.0)	13 (8.4)
Education			
Under diploma	50 (45.9)	14 (30.4)	64 (41.3)
Diploma	31 (28.4)	18 (39.1)	49 (31.6)
Upper diploma	26 (23.9)	14 (30.4)	40 (25.8)
Unknown	2 (1.8)	0 (0.0)	2 (1.3)

^a Values are expressed as No. (%) or mean ± SD (range).

in HIV-1-infected individuals, particularly in older patients. Some studies have shown that older HIV-infected individuals (over 50-years-old) without ART are approximately 10 times more likely to develop SARS-CoV-2 than young HIV-infected patients who continue ART. According to other studies, the use of ART reduces morbidity and mortality of HIV-1-infected individuals with tuberculosis (34, 35).

The interim guidance for COVID-19 and patients with HIV infection indicates that elderly HIV-infected individuals are at the greatest risk of COVID-19 (36). Thus, the on-time availability of ARVs for HIV-infected individuals

is critical during the COVID-19 pandemic (37). No COVID-19 was reported in a study on 199 HIV-infected patients using ritonavir/lopinavir or integrase inhibitors. However, 8/947 patients who used NRTIs and NNRTIs were infected with SARS-CoV-2 (11). In another study, HIV-infected individuals receiving TDF/FTC had a lower risk of developing COVID-19 than those receiving different ART (38). In another study, ART activity for HIV infection, including lopinavir/ritonavir, was effective against SARS or MERS (9). Remdesivir has been shown to be effective, too (39). Some studies have shown that HIV-1-infected individuals

Table 3. Symptoms and Other Diseases of Studied HIV-1-Infected Participants with Positive and Negative Results of Real-Time Polymerase Chain Reaction for SARS-CoV-2^a

Parameters	Real-Time PCR/Positive	Real-Time PCR/Negative
Sex		
Male	4 (33.3)	105 (73.4)
Female	8 (66.7)	38 (26.6)
Symptoms		
Fever	5 (41.7)	4 (2.8)
Confusion	0 (0.0)	2 (1.4)
Headache	3 (25.0)	10 (7.0)
Chills	2 (16.7)	2 (1.4)
Skeletal pain	3 (25.0)	11 (7.7)
Dry cough	7 (58.3)	12 (8.4)
Sputum cough	0 (0.0)	6 (4.2)
Chest pain	0 (0.0)	0 (0.0)
Shortness of breath	0 (0.0)	0 (0.0)
Runny nose	5 (41.7)	8 (5.6)
Cape of nose	0 (0.0)	6 (4.2)
Deceased smell	5 (41.7)	4 (2.8)
Deceased taste	5 (41.7)	4 (2.8)
Gastrointestinal symptom	2 (16.7)	3 (2.1)
Bleeding stomach	0 (0.0)	0 (0.0)
Other		
HCV Ab	4 (33.3)	27 (18.9)
HBsAg	0 (0.0)	2 (1.4)
HBsAb	10 (83.3)	115 (80.4)
Diabetes	0 (0.0)	2 (1.4)
Tuberculosis (TB)	0 (0.0)	4 (2.8)
Kaposi's sarcoma	0 (0.0)	2 (1.4)

^a Values are expressed as No. (%).

treated with ARVs, including tenofovir (TDF) or protease inhibitors, are less likely to become infected with SARS-CoV-2, with less severe COVID-19 (38). However, more studies are necessary to further elaborate on this condition. No significant association was observed in this research between HIV-1-infected individuals with or without COVID-19 and taking ARVs. In the present study, HIV-infected individuals admitted to the hospitals had the HIV viral load rate ranging from 0 to 11136 IU/mL and the CD4 count rate ranging from 65 to 1481 cells/ μ L. No differences were observed in the COVID-19 infection rate among individuals with or without HIV-1 infection. Global studies have shown that comorbidities and age may affect the COVID-19 severity and are not related to HIV infection (40, 41).

In northern Italy, HIV-infected individuals (3.4%) were

infected with SARS-CoV-2 (41). In Spain, HIV-infected individuals (0.92%) were infected with SARS-CoV-2 (32). Another study in New York City reported 88 HIV-infected individuals with COVID-19 hospitalized. Additionally, a history of comorbidities and smoking was more prevalent in HIV-positive individuals than in HIV-negative patients (24). In Wuhan, the COVID-19 prevalence was reported among HIV-infected individuals (0.58%) (37). In Madrid, the COVID-19 prevalence was reported among HIV-infected individuals (1.8%) (12). Similarly, the COVID-19 prevalence among HIV-infected patients (0.6%) was reported in Wuhan, China (11). In Spain, out of 77,590 HIV-1-infected individuals receiving ARVs, 236 were infected with SARS-CoV-2. Among 236 patients diagnosed with COVID-19, hospitalization, ICU admission, and mortality were reported in 151 (64%), 15 (6%),

Table 4. Complete Information About Studied HIV-1-infected Individuals with SARS-CoV-2 Infection or Positive for Anti-SARS-CoV-2 Ab

No.	Sex/Age	Blood Type	COVID-19 Ab	Real-Time PCR	Duration of HIV Infection (y)	CD4 Count	Viral Load (IU/mL)	Antiretroviral Drugs Used by Patients	HIV-1 Subtype
1	M/57	O+	+	+	14	176	0	NRTIs, NNRTIs	CRF35_AD
2	M/30	O-	+	-	3	872	182	NRTIs, NNRTIs	CRF35_AD
3	M/33	O+	+	-	15	860	0	NRTIs, INIs	CRF35_AD
4	F/41	A+	+	-	1	902	0	NRTIs, NNRTIs	CRF35_AD
5	M/50	O+	+	-	11	429	2275	NRTIs, NNRTIs, PIs	CRF01_AE
6	M/47	B+	-	+	3	610	0	NRTIs, NNRTIs	CRF35_AD
7	F/58	O+	-	+	12	884	0	NRTIs, NNRTIs	CRF35_AD
8	F/26	A+	-	+	2	337	214	NRTIs, INIs	CRF35_AD
9	F/32	B+	-	+	4	515	0	NRTIs, NNRTIs	CRF35_AD
10	F/28	AB+	-	+	1	1001	0	NRTIs, NNRTIs	CRF35_AD
11	M/31	O+	+	-	13	803	0	NRTIs, INIs	CRF35_AD
12	M/52	O+	+	-	9	399	2040	NRTIs, NNRTIs, PIs	CRF35_AD
13	F/26	AB+	-	+	1	998	0	NRTIs, NNRTIs	CRF35_AD
14	M/45	A+	-	+	4	643	0	NRTIs, NNRTIs	CRF35_AD
15	F/30	B+	-	+	2	537	0	NRTIs, NNRTIs	CRF35_AD
16	F/55	O+	-	+	11	829	0	NRTIs, NNRTIs	CRF35_AD
17	M/31	O-	+	-	4	853	185	NRTIs, NNRTIs	CRF35_AD
18	F/28	A+	-	+	3	402	221	NRTIs, INIs	CRF35_AD
19	F/39	A+	+	-	1	898	0	NRTIs, NNRTIs	CRF35_AD
20	M/56	O+	+	+	12	189	0	NRTIs, NNRTIs	CRF35_AD

Abbreviations: NRTIs, nucleoside reverse transcriptase inhibitors; NNRTIs, non-nucleoside reverse transcriptase inhibitors; PIs, protease inhibitors; INIs, integrase inhibitors.

and 20 (8%) patients, respectively (38). In China, a positive real-time PCR test was diagnosed for SARS-CoV-2 (62%) (42). The current study findings differ from those of some published studies. In other words, the COVID-19 prevalence was lower in this study than in some studies (42). However, the COVID-19 prevalence was higher in this study than in other studies (12, 32, 37, 41).

In Iran, out of 12,870 individuals, 2,968 hospitalized COVID-19 cases have been diagnosed. Also, 239 deaths have been reported. Moreover, the COVID-19 diagnosis rate was 66% in males. However, the current study findings do not support the previous research performed in Iran (43). In Iran, out of 161 suspected individuals of SARS-CoV-2 in the age range of 50 - 59 years, 102 showed positive real-time PCR test results; among them, a mortality rate of 15.6% was reported, accounting for 16 patients. Furthermore, two patients showed positive real-time PCR test results out of 13 suspected individuals with SARS-CoV-2 in the age range of 0 - 9 years. Moreover, no mortality was observed in these children (44). In Iran, out of 909 participants, 328 (36.08%) were diagnosed with COVID-19 (45). However, the COVID-19 prevalence in this study was lower than the results reported in some studies conducted in Iran (45). This study indicated the COVID-19 infection rate in HIV-1-infected individuals ($n = 12$, 7.7%), unlike previous studies performed among the Iranian population (43, 45). In the present study, the COVID-19 diagnosis rate was higher in females ($n = 8$, 17.4%) than males ($n = 4$, 3.7%). The current study

findings are consistent with a previous study conducted in Iran, showing that the COVID-19 prevalence was higher in women than in men. The incidence of COVID-19 in females and males was reported to be 185 (20.35%) and 143 (15.73%), respectively (45). Out of the nine hospitalized children in Iran, three positive real-time PCR tests for SARS-CoV-2 were reported (46).

The clinical and demographic characteristics of HIV-1-infected individuals with a positive SARS-CoV-2 real-time PCR result in this study differed from those reported in another study conducted in Iran; patients showed fewer symptoms such as fever and dry cough in this study than in another study (47). Moreover, there was no association between the COVID-19 diagnosis and CD4 cell counts in HIV-1-infected individuals in this study. According to our findings, HIV-infected individuals are likely to be at a similar risk for SARS-CoV-2 in clinical manifestations as others in the community. Also, ARVs do not appear to be effective against COVID-19. In this study, HIV-infected patients approximately had a well immunological condition; thus, an incremental risk of COVID-19 was not associated with a low CD4 + count. The present study showed that the risk of developing COVID-19 in HIV-infected individuals was similar to the general population.

In this evaluation, volunteers had various types of blood groups. Out of 12 (7.7%) positive real-time PCR results for SARS-CoV-2, four, three, three, and two HIV-1-infected individuals were identified with O+ blood, A+ blood, B+

blood, and AB+ blood, respectively. Out of the 10 (6.5%) positive results for anti-COVID Ab (IgG) against SARS-CoV-2, the numbers of HIV-1 infected individuals with O+ blood, O- blood, and A+ blood were six, two, and two, respectively. There was no association between the COVID-19 diagnosis and different blood types in HIV-1-infected individuals in this research. However, some studies have shown that people with O blood are less susceptible to COVID-19 (48, 49).

5.1. Conclusions

The present study's primary purpose was to investigate the COVID-19 prevalence among HIV-1-infected patients, focusing on laboratory and epidemiological characteristics of COVID-19 in the Iranian population. However, during the COVID-19 pandemic, the screening and identification of HIV-1-infected individuals were limited. The access to the number of recent HIV-1-infected individuals was affected by COVID-19 limitations. Despite these limitations, this study elaborated on the characteristics of HIV-1-infected individuals with COVID-19 in the Iranian population. Only 12 (7.7%) HIV-1-infected patients were positive for the SARS-CoV-2 real-time PCR test. In this study, females (n = 8, 17.4%) had a higher COVID-19 infection rate than males (n = 4, 3.7%). Nevertheless, males (n = 8, 7.3%) had higher anti-COVID-19 Ab (IgG) than females (n = 2, 4.3%) in total cases (n = 10, 6.5%). During the COVID-19 outbreak, more studies are needed to examine HIV-1-infected individuals' health conditions worldwide.

Acknowledgments

The authors and researchers of the current study especially thank the volunteers for their participation.

Footnotes

Authors' Contribution: Study concept and design: F. BS. and S. G.; Patient enrollment for the research: S. K. and M. JM.; Drafting of the manuscript: F. BS. and K. K.; Critical revision of the manuscript for important intellectual content: S. J. K. and A. M.; Statistical analysis: F. DD., R. B., M. S., and M. AK. All the authors contributed to the final version of the manuscript.

Conflict of Interests: The authors do not declare any actual or potential conflicts of interest.

Data Reproducibility: The data presented in this study are openly available in one of the repositories or will be available on request from the corresponding author by this journal representative at any time during submission

or after publication. Otherwise, all consequences of possible withdrawal or future retraction will be with the corresponding author.

Ethical Approval: This survey was approved by the Ethics Committee of the Iran University of Medical Sciences (IUMS), Tehran, Iran, as per the Helsinki Declaration (ethical code: IR.IUMS.REC.1399.283).

Funding/Support: This survey was fully supported by the Research Deputy of Iran University of Medical Sciences, Tehran, Iran (grant number 17989).

Informed Consent: All participants were informed of the present study, and consent forms were obtained from the volunteers before commencing the study.

References

1. Amodio E, Vitale F, Cimino L, Casuccio A, Tramuto F. Outbreak of Novel Coronavirus (SARS-Cov-2): First Evidences From International Scientific Literature and Pending Questions. *Healthcare (Basel)*. 2020;**8**(1). doi: [10.3390/healthcare8010051](https://doi.org/10.3390/healthcare8010051). [PubMed: [32120965](https://pubmed.ncbi.nlm.nih.gov/32120965/)]. [PubMed Central: [PMC7151147](https://pubmed.ncbi.nlm.nih.gov/PMC7151147/)].
2. Turken M, Altan H, Atalay S, Kose S. The Course of COVID-19 in Four Patients with HIV During the Pandemic. *Curr HIV Res*. 2021;**19**(3):286–91. doi: [10.2174/1570162X18666201201093540](https://doi.org/10.2174/1570162X18666201201093540). [PubMed: [33261541](https://pubmed.ncbi.nlm.nih.gov/33261541/)].
3. Zaim S, Chong JH, Sankaranarayanan V, Harky A. COVID-19 and Multiorgan Response. *Curr Probl Cardiol*. 2020;**45**(8):100618. doi: [10.1016/j.cpcardiol.2020.100618](https://doi.org/10.1016/j.cpcardiol.2020.100618). [PubMed: [32439197](https://pubmed.ncbi.nlm.nih.gov/32439197/)]. [PubMed Central: [PMC7187881](https://pubmed.ncbi.nlm.nih.gov/PMC7187881/)].
4. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. *Lancet Respir Med*. 2020;**8**(4):420–2. doi: [10.1016/S2213-2600\(20\)30076-X](https://doi.org/10.1016/S2213-2600(20)30076-X). [PubMed: [32085846](https://pubmed.ncbi.nlm.nih.gov/32085846/)]. [PubMed Central: [PMC7164771](https://pubmed.ncbi.nlm.nih.gov/PMC7164771/)].
5. Zheng Z, Peng F, Xu B, Zhao J, Liu H, Peng J, et al. Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis. *J Infect*. 2020;**81**(2):e16–25. doi: [10.1016/j.jinf.2020.04.021](https://doi.org/10.1016/j.jinf.2020.04.021). [PubMed: [32335169](https://pubmed.ncbi.nlm.nih.gov/32335169/)]. [PubMed Central: [PMC7177098](https://pubmed.ncbi.nlm.nih.gov/PMC7177098/)].
6. Xu Z, Zhang C, Wang FS. COVID-19 in people with HIV. *Lancet HIV*. 2020;**7**(8):e524–6. doi: [10.1016/S2352-3018\(20\)30163-6](https://doi.org/10.1016/S2352-3018(20)30163-6). [PubMed: [32473658](https://pubmed.ncbi.nlm.nih.gov/32473658/)]. [PubMed Central: [PMC7255755](https://pubmed.ncbi.nlm.nih.gov/PMC7255755/)].
7. World Health Organization. *HIV/AIDS*. Geneva, Switzerland: World Health Organization; 2021. Available from: <https://www.who.int/news-room/fact-sheets/detail/hiv-aids>.
8. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet*. 2020;**395**(10229):1054–62. doi: [10.1016/S0140-6736\(20\)30566-3](https://doi.org/10.1016/S0140-6736(20)30566-3). [PubMed: [32171076](https://pubmed.ncbi.nlm.nih.gov/32171076/)]. [PubMed Central: [PMC7270627](https://pubmed.ncbi.nlm.nih.gov/PMC7270627/)].
9. Park SY, Lee JS, Son JS, Ko JH, Peck KR, Jung Y, et al. Post-exposure prophylaxis for Middle East respiratory syndrome in healthcare workers. *J Hosp Infect*. 2019;**101**(1):42–6. doi: [10.1016/j.jhin.2018.09.005](https://doi.org/10.1016/j.jhin.2018.09.005). [PubMed: [30240813](https://pubmed.ncbi.nlm.nih.gov/30240813/)]. [PubMed Central: [PMC7114948](https://pubmed.ncbi.nlm.nih.gov/PMC7114948/)].
10. Chen XP, Li GH, Tang XP, Xiong Y, Chen XJ, Cao Y. Lack of severe acute respiratory syndrome in 19 AIDS patients hospitalized together. *J Acquir Immune Defic Syndr*. 2003;**34**(2):242–3. doi: [10.1097/00126334-200310010-00016](https://doi.org/10.1097/00126334-200310010-00016). [PubMed: [14526215](https://pubmed.ncbi.nlm.nih.gov/14526215/)].
11. Peng X, Ouyang J, Isnard S, Lin J, Fombuena B, Zhu B, et al. Sharing CD4+ T Cell Loss: When COVID-19 and HIV Collide on Immune System. *Front Immunol*. 2020;**11**:596631. doi: [10.3389/fimmu.2020.596631](https://doi.org/10.3389/fimmu.2020.596631). [PubMed: [33384690](https://pubmed.ncbi.nlm.nih.gov/33384690/)]. [PubMed Central: [PMC7770166](https://pubmed.ncbi.nlm.nih.gov/PMC7770166/)].

12. Vizcarra P, Perez-Elias MJ, Quereda C, Moreno A, Vivancos MJ, Dronda F, et al. Description of COVID-19 in HIV-infected individuals: a single-centre, prospective cohort. *Lancet HIV*. 2020;7(8):e554–64. doi: [10.1016/S2352-3018\(20\)30164-8](#). [PubMed: [32473657](#)]. [PubMed Central: [PMC7255735](#)].
13. Mascolo S, Romanelli A, Carleo MA, Esposito V. Could HIV infection alter the clinical course of SARS-CoV-2 infection? When less is better. *J Med Virol*. 2020;92(10):1777–8. doi: [10.1002/jmv.25881](#). [PubMed: [32293709](#)]. [PubMed Central: [PMC7262314](#)].
14. Ballester-Arnal R, Gil-Llario MD. The Virus that Changed Spain: Impact of COVID-19 on People with HIV. *AIDS Behav*. 2020;24(8):2253–7. doi: [10.1007/s10461-020-02877-3](#). [PubMed: [32342259](#)]. [PubMed Central: [PMC7184942](#)].
15. Kanwugu ON, Adadi P. HIV/SARS-CoV-2 coinfection: A global perspective. *J Med Virol*. 2021;93(2):726–32. doi: [10.1002/jmv.26321](#). [PubMed: [32692406](#)]. [PubMed Central: [PMC7404432](#)].
16. Adadi P, Kanwugu ON. Living with HIV in the time of COVID-19: A glimpse of hope. *J Med Virol*. 2021;93(1):59–60. doi: [10.1002/jmv.26118](#). [PubMed: [32497253](#)]. [PubMed Central: [PMC7300760](#)].
17. Eaton LA, Kalichman SC. Social and behavioral health responses to COVID-19: lessons learned from four decades of an HIV pandemic. *J Behav Med*. 2020;43(3):341–5. doi: [10.1007/s10865-020-00157-y](#). [PubMed: [32333185](#)]. [PubMed Central: [PMC7182505](#)].
18. Shalev N, Scherer M, LaSota ED, Antoniou P, Yin MT, Zucker J, et al. Clinical Characteristics and Outcomes in People Living With Human Immunodeficiency Virus Hospitalized for Coronavirus Disease 2019. *Clin Infect Dis*. 2020;71(16):2294–7. doi: [10.1093/cid/ciaa635](#). [PubMed: [32472138](#)]. [PubMed Central: [PMC7314170](#)].
19. Corman V, Bleickner T, Brünink S, Drosten C, Zambon M. *Diagnostic detection of 2019-nCoV by real-time RT-PCR*. 17. Geneva, Switzerland: World Health Organization; 2020.
20. Wozniak A, Cerda A, Ibarra-Henriquez C, Sebastian V, Armijo G, Lamig L, et al. A simple RNA preparation method for SARS-CoV-2 detection by RT-qPCR. *Sci Rep*. 2020;10(1):16608. doi: [10.1038/s41598-020-73616-w](#). [PubMed: [33024174](#)]. [PubMed Central: [PMC7538882](#)].
21. The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19)-China, 2020. *China CDC Wkly*. 2020;2(8):113–22. doi: [10.46234/ccdcw2020.032](#). [PubMed: [34594836](#)]. [PubMed Central: [PMC8392929](#)].
22. Peeri NC, Shrestha N, Rahman MS, Zaki R, Tan Z, Bibi S, et al. The SARS, MERS and novel coronavirus (COVID-19) epidemics, the newest and biggest global health threats: what lessons have we learned? *Int J Epidemiol*. 2020;49(3):717–26. doi: [10.1093/ije/dyaa033](#). [PubMed: [32086938](#)]. [PubMed Central: [PMC7197734](#)].
23. Liu B, Li M, Zhou Z, Guan X, Xiang Y. Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)? *J Autoimmun*. 2020;111:102452. doi: [10.1016/j.jaut.2020.102452](#). [PubMed: [32291137](#)]. [PubMed Central: [PMC7151347](#)].
24. Sigel K, Swartz T, Golden E, Paranjpe I, Somani S, Richter F, et al. Coronavirus 2019 and People Living With Human Immunodeficiency Virus: Outcomes for Hospitalized Patients in New York City. *Clin Infect Dis*. 2020;71(11):2933–8. doi: [10.1093/cid/ciaa880](#). [PubMed: [32594164](#)]. [PubMed Central: [PMC7337691](#)].
25. Ho HE, Peluso MJ, Margus C, Matias Lopes JP, He C, Gaisa MM, et al. Clinical Outcomes and Immunologic Characteristics of Coronavirus Disease 2019 in People With Human Immunodeficiency Virus. *J Infect Dis*. 2021;223(3):403–8. doi: [10.1093/infdis/jiaa380](#). [PubMed: [32601704](#)]. [PubMed Central: [PMC7337732](#)].
26. Anderson RM, Heesterbeek H, Klinkenberg D, Hollingsworth TD. How will country-based mitigation measures influence the course of the COVID-19 epidemic? *Lancet*. 2020;395(10228):931–4. doi: [10.1016/S0140-6736\(20\)30567-5](#). [PubMed: [32164834](#)]. [PubMed Central: [PMC7158572](#)].
27. Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. *JAMA Intern Med*. 2020;180(7):934–43. doi: [10.1001/jamainternmed.2020.0994](#). [PubMed: [32167524](#)]. [PubMed Central: [PMC7070509](#)].
28. Hong KH, Choi JP, Hong SH, Lee J, Kwon JS, Kim SM, et al. Predictors of mortality in Middle East respiratory syndrome (MERS). *Thorax*. 2018;73(3):286–9. doi: [10.1136/thoraxjnl-2016-209313](#). [PubMed: [28724637](#)].
29. Choi KW, Chau TN, Tsang O, Tso E, Chiu MC, Tong WL, et al. Outcomes and prognostic factors in 267 patients with severe acute respiratory syndrome in Hong Kong. *Ann Intern Med*. 2003;139(9):715–23. doi: [10.7326/0003-4819-139-9-200311040-00005](#). [PubMed: [14597455](#)].
30. Channappanavar R, Fett C, Mack M, Ten Eyck PP, Meyerholz DK, Perlman S. Sex-Based Differences in Susceptibility to Severe Acute Respiratory Syndrome Coronavirus Infection. *J Immunol*. 2017;198(10):4046–53. doi: [10.4049/jimmunol.1601896](#). [PubMed: [28373583](#)]. [PubMed Central: [PMC5450662](#)].
31. Badawi A, Ryoo SG. Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERS-CoV): a systematic review and meta-analysis. *Int J Infect Dis*. 2016;49:129–33. doi: [10.1016/j.ijid.2016.06.015](#). [PubMed: [27352628](#)]. [PubMed Central: [PMC7110556](#)].
32. Blanco JL, Ambrosioni J, Garcia F, Martinez E, Soriano A, Mallolas J, et al. COVID-19 in patients with HIV: clinical case series. *Lancet HIV*. 2020;7(5):e314–6. doi: [10.1016/S2352-3018\(20\)30111-9](#). [PubMed: [32304642](#)]. [PubMed Central: [PMC7159872](#)].
33. Dauby N. Potential impact of COVID-19 in people living with HIV: experience from previous 21st century coronaviruses epidemics. *AIDS*. 2020;34(8):1255–6. doi: [10.1097/QAD.0000000000002555](#). [PubMed: [32501850](#)]. [PubMed Central: [PMC7309641](#)].
34. Uthman OA, Okwundu C, Gbenga K, Volmink J, Dowdy D, Zumla A, et al. Optimal Timing of Antiretroviral Therapy Initiation for HIV-Infected Adults With Newly Diagnosed Pulmonary Tuberculosis: A Systematic Review and Meta-analysis. *Ann Intern Med*. 2015;163(1):32–9. doi: [10.7326/M14-2979](#). [PubMed: [26148280](#)].
35. Worodria W, Ssempijja V, Hanrahan C, Ssegonja R, Muhofwa A, Mazapke D, et al. Opportunistic diseases diminish the clinical benefit of immediate antiretroviral therapy in HIV-tuberculosis co-infected adults with low CD4+ cell counts. *AIDS*. 2018;32(15):2141–9. doi: [10.1097/QAD.0000000000001941](#). [PubMed: [30005014](#)]. [PubMed Central: [PMC6136949](#)].
36. Carreno V, Bartolome J, Castillo I, Quiroga JA. New perspectives in occult hepatitis C virus infection. *World J Gastroenterol*. 2012;18(23):2887–94. doi: [10.3748/wjg.v18.i23.2887](#). [PubMed: [22736911](#)]. [PubMed Central: [PMC3380315](#)].
37. Huang J, Xie N, Hu X, Yan H, Ding J, Liu P, et al. Epidemiological, Virological and Serological Features of Coronavirus Disease 2019 (COVID-19) Cases in People Living With Human Immunodeficiency Virus in Wuhan: A Population-based Cohort Study. *Clin Infect Dis*. 2021;73(7):e2086–94. doi: [10.1093/cid/ciaa1186](#). [PubMed: [32803216](#)]. [PubMed Central: [PMC7454403](#)].
38. Del Amo J, Polo R, Moreno S, Diaz A, Martinez E, Arribas JR, et al. Incidence and Severity of COVID-19 in HIV-Positive Persons Receiving Antiretroviral Therapy: A Cohort Study. *Ann Intern Med*. 2020;173(7):536–41. doi: [10.7326/M20-3689](#). [PubMed: [32589451](#)]. [PubMed Central: [PMC7394316](#)].
39. Goldman JD, Lye DCB, Hui DS, Marks KM, Bruno R, Montejano R, et al. Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. *N Engl J Med*. 2020;383(19):1827–37. doi: [10.1056/NEJMoa2015301](#). [PubMed: [32459919](#)]. [PubMed Central: [PMC7377062](#)].
40. Etienne N, Karmochkine M, Slama L, Pavie J, Batisse D, Usubillaga R, et al. HIV infection and COVID-19: risk factors for severe disease. *AIDS*. 2020;34(12):1771–4. doi: [10.1097/QAD.0000000000002651](#). [PubMed: [3273476](#)]. [PubMed Central: [PMC7493770](#)].
41. Calza L, Bon I, Tadolini M, Borderi M, Colangeli V, Badia L, et al. COVID-19 in patients with HIV-1 infection: a single-centre experience

- in northern Italy. *Infection*. 2021;**49**(2):333–7. doi: [10.1007/s15010-020-01492-7](https://doi.org/10.1007/s15010-020-01492-7). [PubMed: [32748333](https://pubmed.ncbi.nlm.nih.gov/32748333/)]. [PubMed Central: [PMC7397968](https://pubmed.ncbi.nlm.nih.gov/PMC7397968/)].
42. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention. *JAMA*. 2020;**323**(13):1239–42. doi: [10.1001/jama.2020.2648](https://doi.org/10.1001/jama.2020.2648). [PubMed: [32091533](https://pubmed.ncbi.nlm.nih.gov/32091533/)].
 43. Nikpouraghdam M, Jalali Farahani A, Alishiri G, Heydari S, Ebrahimnia M, Samadinia H, et al. Epidemiological characteristics of coronavirus disease 2019 (COVID-19) patients in IRAN: A single center study. *J Clin Virol*. 2020;**127**:104378. doi: [10.1016/j.jcv.2020.104378](https://doi.org/10.1016/j.jcv.2020.104378). [PubMed: [32353762](https://pubmed.ncbi.nlm.nih.gov/32353762/)]. [PubMed Central: [PMC7172806](https://pubmed.ncbi.nlm.nih.gov/PMC7172806/)].
 44. Kalantari H, Tabrizi AHH, Foroohi F. Determination of COVID-19 prevalence with regards to age range of patients referring to the hospitals located in western Tehran, Iran. *Gene Rep*. 2020;**21**:100910. doi: [10.1016/j.genrep.2020.100910](https://doi.org/10.1016/j.genrep.2020.100910). [PubMed: [33047096](https://pubmed.ncbi.nlm.nih.gov/33047096/)]. [PubMed Central: [PMC7540192](https://pubmed.ncbi.nlm.nih.gov/PMC7540192/)].
 45. Abolnezhadian F, Makvandi M, Alavi SM, Azaran A, Jalilian S, Rashno M, et al. Prevalence of SARS-CoV-2 in Patients with Severe Pneumonia in Khuzestan Province, Iran. *Iran J Allergy Asthma Immunol*. 2020;**19**(5):471–7. doi: [10.18502/ijaai.v19i5.4462](https://doi.org/10.18502/ijaai.v19i5.4462). [PubMed: [33463114](https://pubmed.ncbi.nlm.nih.gov/33463114/)].
 46. Rahimzadeh G, Ekrami Noghabi M, Kadkhodaei Elyaderani F, Navaeifar MR, Enayati AA, Manafi Anari A, et al. COVID-19 Infection in Iranian Children: A Case Series of 9 Patients. *J. Pediatr. Rev*. 2020:139–44. doi: [10.32598/jpr.8.2.139](https://doi.org/10.32598/jpr.8.2.139).
 47. Allameh SF, Nemati S, Ghalehtaki R, Mohammadnejad E, Aghili SM, Khajavirad N, et al. Clinical Characteristics and Outcomes of 905 COVID-19 Patients Admitted to Imam Khomeini Hospital Complex in the Capital City of Tehran, Iran. *Arch Iran Med*. 2020;**23**(11):766–75. doi: [10.34172/aim.2020.102](https://doi.org/10.34172/aim.2020.102). [PubMed: [33220695](https://pubmed.ncbi.nlm.nih.gov/33220695/)].
 48. Barnkob MB, Pottegard A, Stovring H, Haunstrup TM, Homburg K, Larsen R, et al. Reduced prevalence of SARS-CoV-2 infection in ABO blood group O. *Blood Adv*. 2020;**4**(20):4990–3. doi: [10.1182/blood-advances.2020002657](https://doi.org/10.1182/blood-advances.2020002657). [PubMed: [33057631](https://pubmed.ncbi.nlm.nih.gov/33057631/)]. [PubMed Central: [PMC7594382](https://pubmed.ncbi.nlm.nih.gov/PMC7594382/)].
 49. Pourali F, Afshari M, Alizadeh-Navaei R, Javidnia J, Moosazadeh M, Hessami A. Relationship between blood group and risk of infection and death in COVID-19: a live meta-analysis. *New Microbes New Infect*. 2020;**37**:100743. doi: [10.1016/j.nmni.2020.100743](https://doi.org/10.1016/j.nmni.2020.100743). [PubMed: [32837730](https://pubmed.ncbi.nlm.nih.gov/32837730/)]. [PubMed Central: [PMC7418722](https://pubmed.ncbi.nlm.nih.gov/PMC7418722/)].